Practical Implementation of the 2016 ATS/CDC/IDSA Treatment Of Drug Susceptible Tuberculosis Guidelines: Caveats and Controversies

[[{"fid":"9907","view_mode":"default","fields":{"format":"default","field_file_image_alt_text[und][0][value]":"Feb 3 2017 Joint Webinar Information ","field_file_image_title_text[und][0][value]":"Feb 3 2017 Joint Webinar Information "},"type":"media","link_text":null,"field_deltas":{"1":{"format":"default","field_file_image_alt_text[und][0][value]":"Feb 3 2017 Joint Webinar Information ","field_file_image_title_text[und][0][value]":"Feb 3 2017 Joint Webinar Information "}},"attributes":{"alt":"Feb 3 2017 Joint Webinar Information ","title":"Feb 3 2017 Joint Webinar Information ","class":"panopoly-image-original media-element file-default","data-delta":"1"}}]]

To view this second presentation, click Practical Implementation of the 2016 ATS/CDC/IDSA Treatment of Drug Susceptible Tuberculosis Guidelines: Caveats and Controversies.

To view the first presentation, click 2016 ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.